220 related articles for article (PubMed ID: 27378269)
1. Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer.
Kangaspeska S; Hultsch S; Jaiswal A; Edgren H; Mpindi JP; Eldfors S; Brück O; Aittokallio T; Kallioniemi O
BMC Cancer; 2016 Jul; 16():378. PubMed ID: 27378269
[TBL] [Abstract][Full Text] [Related]
2. Association of tamoxifen resistance and lipid reprogramming in breast cancer.
Hultsch S; Kankainen M; Paavolainen L; Kovanen RM; Ikonen E; Kangaspeska S; Pietiäinen V; Kallioniemi O
BMC Cancer; 2018 Aug; 18(1):850. PubMed ID: 30143015
[TBL] [Abstract][Full Text] [Related]
3. An integrated bioinformatics approach identifies elevated cyclin E2 expression and E2F activity as distinct features of tamoxifen resistant breast tumors.
Huang L; Zhao S; Frasor JM; Dai Y
PLoS One; 2011; 6(7):e22274. PubMed ID: 21789246
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.
Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L
Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324
[TBL] [Abstract][Full Text] [Related]
5. PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer.
Santiago-Gómez A; Kedward T; Simões BM; Dragoni I; NicAmhlaoibh R; Trivier E; Sabin V; Gee JM; Sims AH; Howell SJ; Clarke RB
Cancer Lett; 2019 Aug; 458():66-75. PubMed ID: 31121213
[TBL] [Abstract][Full Text] [Related]
6. Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties.
Lin X; Li J; Yin G; Zhao Q; Elias D; Lykkesfeldt AE; Stenvang J; Brünner N; Wang J; Yang H; Bolund L; Ditzel HJ
Breast Cancer Res; 2013 Dec; 15(6):R119. PubMed ID: 24355041
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors.
Notas G; Pelekanou V; Kampa M; Alexakis K; Sfakianakis S; Laliotis A; Askoxilakis J; Tsentelierou E; Tzardi M; Tsapis A; Castanas E
Mol Oncol; 2015 Nov; 9(9):1744-59. PubMed ID: 26115764
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
9. Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors.
Faversani A; Vaira V; Moro GP; Tosi D; Lopergolo A; Schultz DC; Rivadeneira D; Altieri DC; Bosari S
Breast Cancer Res; 2014 May; 16(3):R55. PubMed ID: 24886669
[TBL] [Abstract][Full Text] [Related]
10. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells.
Cheng SM; Chang YC; Liu CY; Lee JY; Chan HH; Kuo CW; Lin KY; Tsai SL; Chen SH; Li CF; Leung E; Kanwar JR; Huang CC; Chang JY; Cheung CH
Br J Pharmacol; 2015 Jan; 172(1):214-34. PubMed ID: 25220225
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.
Massarweh S; Osborne CK; Creighton CJ; Qin L; Tsimelzon A; Huang S; Weiss H; Rimawi M; Schiff R
Cancer Res; 2008 Feb; 68(3):826-33. PubMed ID: 18245484
[TBL] [Abstract][Full Text] [Related]
12. Sensitization of estrogen receptor-positive breast cancer cell lines to 4-hydroxytamoxifen by isothiocyanates present in cruciferous plants.
Pawlik A; Słomińska-Wojewódzka M; Herman-Antosiewicz A
Eur J Nutr; 2016 Apr; 55(3):1165-80. PubMed ID: 26014809
[TBL] [Abstract][Full Text] [Related]
13. Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer.
Wu X; Zahari MS; Renuse S; Nirujogi RS; Kim MS; Manda SS; Stearns V; Gabrielson E; Sukumar S; Pandey A
Mol Cell Proteomics; 2015 Nov; 14(11):2887-900. PubMed ID: 26330541
[TBL] [Abstract][Full Text] [Related]
14. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
15. The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance.
Wong C; Chen S
J Steroid Biochem Mol Biol; 2012 Sep; 131(3-5):83-92. PubMed ID: 22265958
[TBL] [Abstract][Full Text] [Related]
16. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
[TBL] [Abstract][Full Text] [Related]
17. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant.
Fan M; Yan PS; Hartman-Frey C; Chen L; Paik H; Oyer SL; Salisbury JD; Cheng AS; Li L; Abbosh PH; Huang TH; Nephew KP
Cancer Res; 2006 Dec; 66(24):11954-66. PubMed ID: 17178894
[TBL] [Abstract][Full Text] [Related]
18. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.
Cittelly DM; Das PM; Spoelstra NS; Edgerton SM; Richer JK; Thor AD; Jones FE
Mol Cancer; 2010 Dec; 9():317. PubMed ID: 21172025
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin enhances the sensitivity of ER‑positive breast cancer cells to tamoxifen by upregulating p73 expression.
Zhu L; Li XX; Shi L; Wu J; Qian JY; Xia TS; Zhou WB; Sun X; Zhou XJ; Wei JF; Ding Q
Oncol Rep; 2019 Jan; 41(1):455-464. PubMed ID: 30542717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
